Bukhtiyarova M, Cook E, Hancock P, Hruza A, Shaw A, Adam G
ACS Med Chem Lett. 2021; 12(1):99-106.
PMID: 33488970
PMC: 7812668.
DOI: 10.1021/acsmedchemlett.0c00551.
Mattingly R
ISRN Oncol. 2013; 2013:536529.
PMID: 24294527
PMC: 3833460.
DOI: 10.1155/2013/536529.
Bellesia F, Choi S, Felluga F, Fiscaletti G, Ghelfi F, Menziani M
Bioorg Med Chem. 2012; 21(1):348-58.
PMID: 23182215
PMC: 3761967.
DOI: 10.1016/j.bmc.2012.10.034.
Yap J, Worlikar S, MacKerell Jr A, Shapiro P, Fletcher S
ChemMedChem. 2010; 6(1):38-48.
PMID: 21110380
PMC: 3477473.
DOI: 10.1002/cmdc.201000354.
Fletcher S, Pusateri Keaney E, Cummings C, Blaskovich M, Hast M, Glenn M
J Med Chem. 2010; 53(19):6867-88.
PMID: 20822181
PMC: 3045627.
DOI: 10.1021/jm1001748.
Working together: Farnesyl transferase inhibitors and statins block protein prenylation.
Wojtkowiak J, Gibbs R, Mattingly R
Mol Cell Pharmacol. 2010; 1(1):1-6.
PMID: 20419048
PMC: 2858423.
DOI: 10.4255/mcpharmacol.09.01.
Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
DeGraw A, Keiser M, Ochocki J, Shoichet B, Distefano M
J Med Chem. 2010; 53(6):2464-71.
PMID: 20180535
PMC: 2867455.
DOI: 10.1021/jm901613f.
Synthesis and anticancer activity of new hydroxamic acid containing 1,4-benzodiazepines.
Tardibono L, Miller M
Org Lett. 2009; 11(7):1575-8.
PMID: 19320504
PMC: 2725444.
DOI: 10.1021/ol900210h.
Caged protein prenyltransferase substrates: tools for understanding protein prenylation.
DeGraw A, Hast M, Xu J, Mullen D, Beese L, Barany G
Chem Biol Drug Des. 2008; 72(3):171-81.
PMID: 18844669
PMC: 2680146.
DOI: 10.1111/j.1747-0285.2008.00698.x.
Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation.
Fletcher S, Cummings C, Rivas K, Katt W, Horney C, Buckner F
J Med Chem. 2008; 51(17):5176-97.
PMID: 18686940
PMC: 3049929.
DOI: 10.1021/jm800113p.
Farnesyl diphosphate analogues with omega-bioorthogonal azide and alkyne functional groups for protein farnesyl transferase-catalyzed ligation reactions.
Labadie G, Viswanathan R, Poulter C
J Org Chem. 2007; 72(24):9291-7.
PMID: 17979291
PMC: 2516946.
DOI: 10.1021/jo7017747.
Peptidomimetics in cancer chemotherapy.
Avendano C, Menendez J
Clin Transl Oncol. 2007; 9(9):563-70.
PMID: 17921103
DOI: 10.1007/s12094-007-0104-6.
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials.
Bendale P, Olepu S, Suryadevara P, Bulbule V, Rivas K, Nallan L
J Med Chem. 2007; 50(19):4585-605.
PMID: 17722901
PMC: 2894570.
DOI: 10.1021/jm0703340.
Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase.
Eastman R, White J, Hucke O, Yokoyama K, Verlinde C, Hast M
Mol Biochem Parasitol. 2007; 152(1):66-71.
PMID: 17208314
PMC: 2875941.
DOI: 10.1016/j.molbiopara.2006.11.012.
Computational studies of the farnesyltransferase ternary complex part I: substrate binding.
Cui G, Wang B, Merz Jr K
Biochemistry. 2005; 44(50):16513-23.
PMID: 16342942
PMC: 2566548.
DOI: 10.1021/bi051020m.
Synthesis of desthio prenylcysteine analogs: sulfur is important for biological activity.
Henriksen B, Anderson J, Hrycyna C, Gibbs R
Bioorg Med Chem Lett. 2005; 15(22):5080-3.
PMID: 16183278
PMC: 3401638.
DOI: 10.1016/j.bmcl.2005.07.075.
